Using Microgenics unique technology, cloned enzyme donor immunoassay (CEDIA), the multiplex assay (CEDIA Amphetamines/Ecstasy) has been developed for the detection of amphetamine, methamphetamine, and ecstasy drugs at cutoff level either of 500 ng/mL or 1000 ng/mL applicable for either qualitative screening or semiquantitative measurement. The multiplex assay detects the total concentration of amphetamine, methamphetamine, and ecstasy drugs in urine samples. In addition, the assay detects metabolites of parent drugs and structurally related drugs including d,l-amphetamine (67.2%), d,l-methamphetamine (58.4%), MDA (113%), MDMA (199%), MDEA (207%), MBDB (123%), BDB (72%), PMA (24%), and PMMA (100%). The assay is highly specific and exhibits minimal cross-reactivity with the undesirable, structurally related over-thecounter amphetaminelike drugs. Imprecision results (n = 120) demonstrate an intra-assay < 6.3% CV and an interassay < 9.2% CV as performed by a modified NCCLS protocol. Using the SAMHSA mandatory guidelines of a 500.ng/mL cutoff for the immunoassay and a 250-ng/mL cutoff for GC-MS, the assay detects 164 out of 165 GC-MS-positive samples. For drug abuse testing, the multiplex assay presents an excellent method for the detection of multiple drugs with greater sensitivity and broader detection.
Introduction
Amphetamine and its derivatives are sympathomimetic amines with central nervous system (CNS) stimulant activity (1, 2) . They have been classified as Schedule II drugs in the U.S. since 1969, and currently may be prescribed for the treatment of narcolepsy, obesity, and childhood attention deficit disorders (ADD) (2, 3) . Side effects at low doses of amphetamines include irritability, anxiety, insomnia, blurred vision, increased blood pressure, and heart palpitations (2, 3) . Chronic, high-dose users may develop a psychosis that can be indistinguishable from acute schizophrenia (2, 3) . Amphetamines are rapidly absorbed from the gastrointestinal tract and distributed widely throughout the body (3) . Metabolism occurs in liver either by deamination or hydroxylation of the aromatic ring and (or) side chain. Approximately 70% of amphetamine and 62% of methamphetamine dose is eliminated in the urine within 24 h after administration (3) (4) (5) .
Methylenedioxymethamphetamine (MDMA, ecstasy) is the leading molecule of a group of ring-substituted methylenedioxy analogues of amphetamines, including MDMA, methylenedioxyamphetamine (MDA), methylenedioxyethylamphetamine (MDEA), N-methyl-l-(3,4-methylenedioxyphenyl)-2-butanamine (MBDB), and 1-(3,4-methylenedioxyphenyl)-2-butanamine (BDB) (6) (7) (8) . The chemical structures of major ecstasy drugs and metabolites are shown in Figure 1 . These drugs are CNS stimulants and are highly popular as "rave" drugs (6) (7) (8) (9) . MDMA is metabolized by Ndemethylation to MDA. Urinary excretion accounts for about Reproduction (photocopying) of editorial content of this journal is prohibited without publisher's permission.18% 3,4-dihydroxymethamphetamine (HHMA), 23% 4-hydroxy-3-methoxymethamphetamine (HMMA), 1.5% MDA, and the remaining as parent drug in the first 24 h of drug dose. At low doses, both MDA and MDMA produce euphoria, increased self-awareness, and an increased sense of trust (10) . At higher doses, they are hallucinogenic. Toxic effects are similar to those of other CNS stimulants and include anxiety, depression, elevated blood pressure, cardiac arrythmia, pupil dilation, and sleep disorders.
Homogeneous immunoassays for detecting amphetamines in biological fluid include CEDIA DAU Amphetamines assay, Dade Behring EMIT II Amphetamine/Methamphetamine assay, Abbott TDx Amphetamine/Methamphetamine assay, and Roche Online Amphetamines assay (11) (12) (13) . Such assays offer a preliminary screening result; however, a specific chemical method must be used for the screened-positive samples to obtain a confirmed analytical result. Gas chromatography-mass spectrometry (GC-MS) is defined by SAMHSA (Substance Abuse and Mental Health Service Administration) as a confirmatory method (14) . The CEDIA DAU Amphetamines assay has employed a two monoclonal antibodies, one specific for amphetamine and the other specific for methamphetamine. Because of the increase in abuse of ecstasy drugs in combination with amphetamines (6) (7) (8) (9) (10) (11) (12) (13) , there is a strong need to incorporate the ecstasy drug testing into the CEDIA DAU Amphetamines assay. In this report, we describe the development and performance of a multiplex assay (CEDIA Amphetamines/Ecstasy assay) for effective testing of amphetamine, methamphetamine, and ecstasy drugs in human urine.
Materials and Methods

Assay principle
The multiplex CEDIA Amphetamines/Ecstasy assay uses the genetically engineered enzyme fragments of enzyme donor (ED) and enzyme acceptor (EA) from ~-D-galactoside galactohydrolase (E. C. 3.2.1.23) or 13-galactosidase (~-gal) from E. coli. The generation of ED and EA, and the CEDIA homogeneous assay have been reported previously (15, U.S. Patent No. 4,708,929). The multiplex assay consists of multiple labels for the detection of amphetamine, methamphetamine, and ecstasy drugs. In the assay, ED was covalently linked to each drug derivative in which each drug derivative is recognized by its specific antibody and the ED is capable of complementation with EA to form active [3-galactosidase enzyme. The enzyme substrate chlorophenolred-13-D-galactopyranoside (CPRG) is then cleaved by the active enzyme into galactose and CPR, and CPR is measured by absorbency at wavelength 570 nm. The antibodies bind to ED conjugates and inhibit the enzyme formation. Calibrators or samples containing amphetamines and/or ecstasy drugs compete with the conjugates for the antibodies. The amount of free conjugates in the assay system is proportional to the concentration of amphetamines and/or ecstasy drugs in the samples or calibrator. Using this assay principle, typical calibration curves are demonstrated as shown in Figure 2 .
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Materials
One hundred sixty-five GC-MS-positive samples were collected from anonymous amphetamine and ecstasy users at Rotterdam, Netherlands. Ninety-one negative samples were collected from healthy volunteers. CEDIA Amphetamines/ Ecstasy assay kits and CEDIA DAU Amphetamines assay kits were obtained from Microgenics Corporation (Fremont, CA). Fluorescence Polarization Immunoassay (FPIA) AmphetaminelMethamphetamine kits were purchased from Abbott Laboratories (Abbott Park, IL). EMIT II Amphetamine/Methamphetamine kits were acquired from Dade Behring Diagnostics (San Jose, CA).
Immunoassays and GC-MS analysis
Immunoassays were performed according to product inserts or technical instructions (16--18) . GC-MS analyses of positive samples were carried out by Dr. L.J. Mostert at Deltalab (Rotterdam, the Netherlands), Dr. M.A. EISohly at EISohly Laboratories, and Microgenics GC-MS department.
Multiplex CEDIA Amphetamines/Ecstasy assay reagents and methods
The assay kit contains four reagents including EA reagent, ED reagent, EA reconstitution buffer, and ED reconstitution buffer. EA reagent was formulated with 0.156 g/L EA, antibodies to amphetamine and methamphetamine, buffer, salt, detergent, and preservative. ED reagent contains 24.42 p.g/L conjugates, 1.67 g/L CPRG, and preservative. EA reconstitution buffer contains antibody to ecstasy drugs, PIPES buffer, salt, and preservative. ED reconstitution buffer contains PIPES buffer, salt, and preservative. Calibrators used CEDIA DAU multi-drug calibrators which consist of drug, urine matrix, and preservative. Prior to the assay, ED reagent was reconstituted with ED buffer and EA reagent with EA buffer. Hitachi clinical analyzers were used for the study. The assay protocol for Hitachi 717 analyzer is listed as an example, 130 IlL R1 (EA reagent) and 130 p.L R2 (ED reagent). The reading frame is at cycle 45--50. The assay can be performed for two cutoffs, 500 ng/mL and 1000 ng/mL by using 6-1~L and 3-1iL samples, respectively. Reagent stability in the assay kit was tested and established individually for the detection of amphetamine, methamphetamine, and ecstasy drugs, although the assay is a multiplex assay.
Results
Calibration curve
Typical calibration curves of amphetamine, methamphetamine, and ecstasy drug (MDA) assays are shown in Figure  2 for the 500-ng/mL cutoff assay. The assay was formulated to give identical cutoff points for amphetamine, methamphetamine, and ecstasy drug. A similar calibration curve was also developed for the 1000-ng/mL cutoff assay (data not shown). Each analyte can be solely measured, if only one of the three drugs is present in the patient's sample. However, the assay simultaneously measures the sum of multiple drugs of amphetamine, methamphetamine, and ecstasy drags. As shown in Figure 2 , both MDMA and MDEA revealed higher dose response curves, resulting in 199% and 207% cross-reactivity, respectively.
Qualitative measurement and semiquantitative measurement
The assay can be used as a qualitative screening in distinguishing positive samples from the negative. Samples producing response values equal to or greater than that of the cutoff calibrator are reported as positives, otherwise as negatives. When multiple levels of calibrator are used in the assay, the assay is utilized as a semiquantitative measurement. The assay calibration curve can be performed using a point to point, or a curve-fitting program. The drug concentration in sample is extrapolated from the calibration curve and reported in ng/mL.
Sensitivity and assay imprecision
For the qualitative measurement using ecstasy drug calibrator, the limit of detection (LOD), defined as 3 SD of 21 replicates of the negative calibrator, is 35 ng/mL and 75 ng/mL for the 500-ng/mL and 1000-ng/mL cutoff protocols, respectively. The LOD, defined by the same manner of qualitative measurement, for the semiquantitative application is 41 ng/mL and 99 ng/mL for the 500-ng/mL and 1000-ng/mL cutoff assay, respectively. The 500-ng/mL cutoff assay used the 500-ng/mL calibrator for data analysis, and the 1000-ng/mL cutoff assay utilized the 1000-ng/mL calibrator for data anaylsis. assay with 500-ng/mL cutoff. Individual calibration curve was generated using its respective drug calibrator. The same assay reagents were used in all calibration curves. The assay was performed using Hitachi 717 clinical analyzer. MDA and MDMA curves were also included to reveal the cross-reactivity. Table I . Results (n = 120) were obtained using a modified NCCLS protocol which tested controls in 6 replicates twice daily for 10 days. The % CV for the qualitative measurement was calculated using the rate measurement in mA/min. The intra-assay imprecision ranged from 1.0% to 2.0% CV, and the interassay imprecision was from 1.8% to 2.8% CV. The imprecision results of semiquantitative assay are listed in Table II . The intra-assay imprecision ranged from 5.0% to 6.3% CV, and the interassay imprecision was from 7.8% to 9.2% CV.
Method comparison
Urine samples including 165 positives and 91 negatives were measured by the CEDIA Amphetamines/Ecstasy assay at 500-ng/mL cutoff using the Hitachi 717 analyzer and by GC-MS as a confirmatory method at 250-ng/mL cutoff. Results are tabulated in Table III 89/91 x 100%]. The false-negative sample by CEDIA Amphetamines/Ecstasy assay contained 502 ng/mL amphetamine by GC-MS. Two false-positive samples by CEDIA Amphetamines/Ecstasy assay contained 392 ng/mL amphetamine and 40 ng/mL MDEA by GC-MS, respectively. 
Specificity
To determine the assay specificity, amphetamines and ecstasy drugs structurally related and unrelated compounds were tested with the CEDIA Amphetamines/Ecstasy assay with a 500-ng/mL cutoff. The percent cross-reactivity of compounds including parent drugs, metabolites of amphetamine, methamphetamine, and ecstasy drugs is shown in Table V . Briefly, the significant cross-reactivity was demonstrated with MDA 113%, MDMA 199%, MDEA 207%, MBDB 123%, BDB 72%, PMMA 100%, PMA 24%, 4-chloroamphetamine 37.9%, fenfluramine 37.6%, and p-hydroxyamphetamine 16.2%. However, two main MDMA metabolites, HMMA and HHMA, were not tested because of unavailability. Compounds structurally unrelated to the parent drugs were also tested and gave a negative response (less than 0.1% crossreactivity) when tested at the concentrations listed in Table VI .
Interference substances
Thirteen interference substances spiked into normal urine samples were tested in the CEDIA Amphetamine/Ecstasy assay. Results were shown in Table VII . The multiplex assay can tolerate interference from these endogenous substances at high limits of concentrations.
Discussion
The design of the multiplex assay is a unique approach to detect three drugs and their metabolites simultaneously for samples from multiple drug use or dose with mixed drugs. In other words, the multiplex assay increases the efficacy of the ex- isting CEDIA DAU Amphetamines assay to detect ecstasy drugs in addition to amphetamines and methamphetamines. CEDIA Amphetamines/Ecstasy assay achieved the design goal by using three monoclonal antibodies and conjugates of ED-drug derivatives in one assay system. Each monoclonal antibody is specific for its respective drug and corresponding metabolites. The testing result reflects a single drug concentration if the sample contains a single drug in the urine sample. Otherwise, the testing result reveals a combination of multiple drug concentrations. Although a single ecstasy test is an option, the current need in drug testing prefers a multiplex assay to screen a combination of ecstasy drugs and amphetamines. The multiplex assay is suitable for qualitative and semiquantitative measurement depending on the individual laboratory need. The assay demonstrates suitable sensitivity and good precision as shown in the result section.
In the method comparison study, the CEDIA Amphetamines/Ecstasy assay screened positive for 164 out of 165 GC-MS positives and negative for 89 out of 91 GC-M8 negatives. The screening sensitivity was calculated as 99.4% and the screening specificity was as 97.8%. Although the immunoassay is not a perfect screening method, the GC-MS method may miss compounds detected by immunoassays due to its ability to detect parent compounds only.
Twenty-three low drug concentration samples were analyzed by various methods including GC-MS, CEDIA Amphetamines/Ecstasy assay, CEDIA DAU Amphetamines assay, TDx Amphetamine/Methamphetamine assay, and EMIT II Amphetamine/Methamphetamine assay. It is difficult to analyze all metabolites or compounds in urine samples by GC-MS. Each immunoassay quantifies all parent drugs, metabolites, and possible other compounds recognized by its antibody. With these limitations, results were analyzed using a cutoff proposed by SAMHSA mandatory guidelines (14) for GC-MS at 250 ng/mL and immunoassay at 500 ng/mL. CEDIA Amphetamines/Ecstasy assay detected 22 of 23 as positive, CEDIA Amphetamines assay detected 10 of 23, TDx assay detected 20 of 23, and EMIT assay detected 8 of 23. A similar trend of detection rate was reported by Zhao et al. (11) . CEDIA Amphetamines/ Ecstasy assay detected most of the positive samples (22 of 23) and missed one sample with 502 ng/mL amphetamine by GC-MS. The higher detection rate of CEDIA Amphetamine/Ecstasy assay is contributed to higher detection toward MDA, MDMA, MDEA, and PMA. The CEDIA Amphetamines assay and EMIT assay detected similarly due to low cross-reactivity with ecstasy drugs. The cross-reactivity of MDA and MDMA is 33% 1,000,000 Methadone 1,000,000 Morphine 1,000,000 Nifedipine 1,000,000 Phencyclidine 250,000 Phenobarbital 1,000,000 d-Propoxyphene 1,000,000 Ranitidine I00,000
Salicyluric acid I00,000 Secobarbital 1,000,000 11-nor-delta 9-THC-COOH Recently, it has become evident that para-methoxyamphetamine (PMA) and para-methoxymethamphetamine (PMMA) are also being mixed with ecstasy drugs, amphetamine and methamphetamine (19) . Unlike the stimulant ecstasy drug, PMA and PMMA are euphoria-producing drugs and have deadly side effect. PMA and PMMA are detected by CEDIA Amphetamine/Ecstasy assay with a cross-reactivity of 24% and 100%, respectively. The two false-positive samples in Table IV may very well contain PMA and/or PMMA that were not measured by GC-MS. Unfortunately, because of insufficient sample volume, those samples were not re-tested by GC-MS for PMA and PMMA. It is important to emphasize that additional studies are warranted to understand the content and effects of PMA and PMMA in the drug user community.
In summary, the multiplex assay demonstrates greater sensitivity and broader detection of amphetamines and ecstasy drugs. With the multiplex detection nature, the assay is accurate and precise, and is ideal as a screening method for multiple abuse drugs. Further studies in drug-screening laboratories are ongoing to better assess and promote clinical utility of the multiplex assay.
